BCLI Latest Report
1min read Financial Performance
BrainStorm Cell (stock code: BCLI) recorded an operating revenue of -318,900 yuan at the end of 2024, an improvement from -4,804,000 yuan at the end of 2023. This change indicates an improvement in the company's performance in terms of operating revenue, but it remains in a loss-making state.
Ask Aime: Why is BrainStorm Cell (BCLI) still in loss despite improved operating revenue?
Key Financial Data
1. BCLI's operating revenue at the end of 2024 was -3,189,000 yuan, an improvement of 1,615,000 yuan from -4,804,000 yuan at the end of 2023, indicating progress in revenue generation.
2. The company's expenses on marketing and management decreased from 31,060,000 yuan to 14,660,000 yuan, indicating some success in cost control.
3. Research and development expenses slightly increased from 16,980,000 yuan to 17,230,000 yuan, indicating the company's ongoing development of new products.
Peer Comparison
1. Industry-wide analysis: The overall biopharmaceutical industry has recovered from the pandemic, with some companies achieving revenue growth. bcli, as a member of the industry, may benefit from the overall recovery but faces the risk of intensified competition.
2. Peer evaluation analysis: Compared to its peers, BCLI's operating revenue remains significantly lower than some competitors in the industry, although it has improved, and it still needs to work to enhance its market share and revenue level in the overall market.
Summary
BCLI's operating revenue has improved but remains in a loss-making state, indicating the challenges the company faces in its operations and market environment. Although it has achieved some success in cost control and research and development, it still needs to strengthen its sales strategy to enhance its overall revenue level.
Opportunities
1. Potential revenue growth from the launch of new products, especially the clinical progress of NurOwn.
2. Expansion of international business and increased market demand, which may further drive revenue growth.
3. The potential to achieve a profit through the impact of non-current losses and profits in the future.
Risks
1. Intensified competition in the market may affect the company's revenue growth and market share.
2. Although research and development expenses have increased, they have not yet translated into positive income in the short term, and the risk of continued losses needs to be watched.
3. Changes in the macroeconomic and industry environment may have a negative impact on the company's operations.
